Get started

Stockstobuy

Allcargo Logistics analysisALLCARGO LOGISTICS 9EMA - 454.95 20EMA - 438.80 50EMA - 409.60 100EMA - 379.3 200EMA - 344.2 Good ROE(Last 5yrs) - 14%+ EPS has grown from a range of 6 to 42(current) Strong cash flow Strong ROCE(26) over the past 5yrs(15) Improved Book value(148cr) compared to 5yrs back(80cr) Zero pledged percentage Recently created a new 52nd week high Stock P/E(11) vs Industry P/E(25) This Stocks benefits from lower Crude Oil prices An undervalued stock which has great potential to grow Technically Strong Stock RSI showing strength Continuation of good volumes for this stock could end up with a new HIGH Recommended for a buy at CMP or on dips for a target of 490+ with a stop loss of below 455
NSE:ALLCARGOLong
by ruelfernandes
Walchandnagar Industries waking up from slumber. Walchandnagar Industries Ltd. is a Heavy Engineering company which has its operations in Engineering, Fabrication and manufacturing for Sugar plants, Industrial and Marine gears, Defense, Aerospace, Nuclear power, Railway etc. Its CMP is 65.7. The negatives of the company are that they have high promoter pledge, decline in quarterly net profits and book value per share is deteriorating. The positive of Walchandnagar are that they have improving net cash flow, return on capital employed (ROCE) And return on equity (ROE) increasing. Entry can be taken after losing over 68 levels. Target will be 71.8 and 75.9. Long term target can be 85 in this stock. Stop loss in the company can be maintained at closing below 57. Educational Purpose / For Paper Trading only.
NSE:WALCHANNAGLong
by Happy_Candles_Investment
Bajaj Healthcare looking good. Bajaj Healthcare Ltd. is a pharmaceutical company which is into the operations of manufacturing of amino acids, nutritional supplements and other pharmaceutical ingredients. Its CMP is 400.1. Negatives of Bajaj Healthcare are that they have declining net cash flow and FII are decreasing their stake in the company. The positives are that they have Zero promoter pledge and increase in operating profit margins. X/2 Entry in Bajaj Healthcare can be taken above 408 and X/2 above 431. Targets will be 462 and 496. Stop Loss can be kept at a closing below 360. Educational purpose / Paper Trading only.
NSE:BAJAJHCARELong
by Happy_Candles_Investment
LU Lufax Most Undervalued Chinese StockFor the China reopening thesis i think LU Lufax Holding is the one of the most undervalued stocks you can own right now! And i will tell you why! LU Lufax Holding has a ridiculous PE Ratio (TTM) of only 1.81! The Forward Dividend & Yield is 0.51 (21.79%)! Last year the stock was $18.30. It has lost most than 90% of its value, while the business is growing and pays dividends. The yield alone is a big gain, even if the price stays flat. Last year Morgan Stanley had a price target for LU of $13 while JPMorgan Chase of $15. 3rd biggest shareholder is BlackRock, with an estimated average of $6.11. You can but the stock now 3 times cheaper than BlackRock. The average daily volume in the past 3 months is high, more than $10Mil daily (i think someone is accumulating). My price target is the $7.10 resistance. I believe LU is a premium call. Looking forward to read your opinion about it!
NYSE:LULong
by TopgOptions
3
Buy persistent above 3400 for target of 3850 Good swing trade only buy if the levels are broken Price has touched 3 time same zone and bounced back and you can see that it is demand zone good support area And a resistance of near 4000 good swing trade holding period is 3 to 4 weeks Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
NSE:PERSISTENTLong
by TraderRavikiran
Results of annual general meeting declared by Universal IbogaineAround 6 million Canadians will meet addiction during their lifetime, according to the Canadian Mental Health Association. With 22,828 total fatalities in Canada over a five year period, the opioid crisis marks one of the most extreme types of addiction. The fatality rate is rising year to year. Universal Ibogaine constantly working on a mission to transform addiction treatment using ibogaine through a planned Canadian clinical trial focused on opioid use disorder. Recently universal ibogaine declared the results and Investors are very happy with the latest press release of $IBO as all resolutions were passed by the requisite majority of shareholders at its annual general meeting which was held on October 3, 2022 in Vancouver. The shareholders also approved the re-appointment of Deloitte LLP as auditors of the Company for the ensuing year, and approved the Company’s 2021 Stock Option Plan, the Company’s 2022 Equity Incentive Compensation Plan and the Company’s 2022 Stock Option Plan. TSXV:IBO universalibogaine.com/universal-ibogaine-announces-results-of-annual-general-meeting/ Universal ibogaine plans to transform addiction management, while developing ibogaine as a central component of innovation for addiction treatment. · Universal ibogine engaged in acquiring an active addiction treatment center in Canada to perfect the wrap-around treatments and roll out ibogaine once approved in Canada. Also partnering with Canadian First Nations to investigate treatment possibilities on sovereign indigenous territories. · Universal ibogaine has developed a state of the art holistic addiction treatment protocol at its Kelburn clinic that, when paired with planned ibogaine detox protocol. It is also intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction. Universal ibogaine , one of the versatile bio technology companies, was created with the goal of medicalizing ibogaine for addiction treatment in Canada and then globally. TSX-V:IBO
TSXV:IBO
by Matthew-Davies1705
1
Global battery management market is expected to reach USD 5.4 B$GEMS.C – Great opportunity to capture the expanding Global battery management market. Although COVID-19 negatively impacted the global battery management market in 2020, it is expected to reach USD 5.4 billion in 2022. It is projected to register a CAGR of over 4.85% during the forecast period (2022-2027). Now the market has reached the pre-pandemic level. The battery management system is meant to track the aspects of the battery system and its cells and use the information gathered to reduce safety hazards and improve battery performance. High demand for battery management systems will accelerate the market growth of battery management systems. This is the perfect opportunity to occupy a significant market share of any lithium mining and supplying company. prnewswire.com/news-releases/global-battery-management-system-market-expected-to-reach-5-4-billion-in-2022--301658228.ht ml $GEMS.C is the leading single sources supplier of critical energy minerals used for clean and green energy evolution. As lithium is a crucial element for the battery management system, Infinity stone venture corporation continuously focuses on a smooth supply of critical energy minerals. * Investors in the Infinity stone venture get exposure to lithium, graphite, copper, cobalt, nickel, manganese, and possibly some PGMs & REEs. * Infinity's lithium mining portfolio is impressive; four projects, 11k+ hectares, 65+ pegmatites, tens of km of a prospective strike — very near or bordering Patriot Battery Metals * infinity stone venture successfully confirmed historically mapped pegmatites and identified new showings. Eighty-seven samples were collected over 3,850 hectares of claims adjacent to the Patriot discovery. $GEMS.C has a bright future in the global battery management market and is constantly fulfilling the demand for critical energy minerals through its eco-friendly mining program. It has government tax incentives and grants, including Canada's 30% Critical Mineral Flow-Through Tax Credit. (CSE: GEMS) (OTC: GEMSF)
CSE:GEMS
by Matthew-Davies1705
Will earnings Season push S&P to new lows? With the latest US earnings season underway, plenty of investors are still wary of making investment decisions. They hope that the earnings results will serve as guidance as to how the next few months will look like before factoring in fresh monetary policies and inflationary measures. Earnings and the S&P 500 In the lead up to the earnings season, A Bloomberg survey showed that more than 60% of its 724 respondents believed the third-quarter earnings season will push the S&P 500 index lower. But data from American financial data and software company FactSet is painting a different picture, revealing analysts' expectation of a roughly 7.5% growth in the earnings for S&P 500 companies for this year and the next, despite investors' fear of a worsening economic downturn. Federal Rate decision While investors are seeking clarity from the third-quarter earnings season, industry players and analysts are united in the belief that the Federal Reserve's rate decision will likely override any positive momentum and have major impact to stock performance moving forward. JPMorgan CEO Jamie Dimon said depending on whether the Federal Reserve engineers a soft or hard landing for the economy, the S&P 500 could fall another 20%. It came with a warning on Monday that the US would likely fall into a recession over the next six to nine months. In contrast, the International Monetary Fund, said Tuesday that it expects the US economy to grow 1%. The price of goods and services in the US continued to grow in September, with the consumer price index 8.2% higher than the prior-year period. The Federal Reserve and some economists maintain that demand generated by a hot labor market and higher wages fuel inflation and that higher unemployment and interest rates are the solution to bring it down. President of Yardeni Research Ed Yardeni expects the S&P 500 to wait until the end of 2023 to be back at its peak, while other analysts are betting on an improving outlook that will push stock prices higher, the New York Times reported.
SP:SPX
by BlackBull_Markets
Twitter ($TWTR) Can Rise Much Higher, Wait For A BreakoutTraders and Investors, Twitter currently is at an important structure zone. If that zone is broken and confirmed, it can rise much higher to the targets shown in the chart. Please support this analysis by liking and sharing. 👍🙂 Rules: 1. Never trade too much 2. Never trade without a confirmation 3. Never rely on signals, do your own analysis and research too ✅ If you found this idea useful, hit the like button, subscribe and share it in other trading forums. ✅ Follow me for future ideas, trade set ups and the updates of this analysis ✅ Don't hesitate to share your ideas, comments, opinions and questions. Take care and trade well -Vik ____________________________________________________ 📌 DISCLAIMER The content on this analysis is subject to change at any time without notice, and is provided for the sole purpose of education only. Not a financial advice or signal. Please make your own independent investment decisions. ____________________________________________________
NYSE:TWTRLong
by vikinsa
EVFM 53X Upside potential according to Morgan Stanley !EVFM Evofem Biosciences has a big upcoming catalyst: Its Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women is on track to report top-line data from this landmark trial in mid-October, so we are one week away from results! Positive study outcomes would enable potential U.S. approval for prevention of these sexually transmitted infections in 2023. Evofem`s Phexxi whas already approved in Nigeria, the most populous country in Africa and the seventh largest country in the world, 3 days ago. On 4/12/2022 Jeffrey Hung from Morgan Stanley Boosted the Price Target for EVFM to Underweight, from $7.95 to $8.55. On 8/15/2022 HC Wainwright Boosted the Price Target to $4.00, giving a Buy Rating. Now the stock is trading at all time low, $0.16, while 4 months ago it was trading 10X higher. In my opinion this is a premium call and a great buy opportunity ahead of a Big upcoming catalyst for EVFM Evofem Biosciences. Looking forward to read your opinion about it.
OTC:EVFMLong
by TopgOptions
1